Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Kala Pharmaceuticals (KALA) Misses Q3 EPS by 1c
November 7, 2019 7:23 AM ESTKala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($0.68), $0.01 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.45 million versus the consensus estimate of $3.64 million.
INVELTYS demonstrated growing demand in the third quarter, with positive feedback from physicians and a... More
